Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide in Previously Untreated, Symptomatic CLL
NCT00751296Phase 2Terminated
- Sponsor
- University Health Network
- Start
- Aug 2006
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in chronic lymphocytic leukemia (CLL), sponsored by University Health Network. Primary endpoint: Efficacy (Response Rate). Started Aug 2006; status: terminated.
02
Drugs
lenalidomide
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00751296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00751296.